206 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00770 | A specific Eps8/EGFR Inhibitor Peptide 327 | EFLDCFQKF | A specific Eps8/EGFR Inhibitor Peptide 327 | Immune response to tumor cell recognition | Lactate dehydrogenase (LDH)-release assay | PC-3 | Pancreatic cancer | IC50 : 83.44 ± 4.62 μM |
| dbacp00824 | AaeAP1 | FLFSLIPSVIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | PC-3 | Human prostate carcinoma | MIC : 10−4 to 10−9 M |
| dbacp00832 | AaeAP2 | FLFSLIPSAIAGLVSAIRN | Venom, Aeneas fattailed scorpion, Africa | Membrane lysis | MTT assay | PC-3 | Human prostate carcinoma | MIC : 10−4 to 10−9 M |
| dbacp00979 | Adenoregulin | GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV | South American frog, Giant leaf frog | Cell membrane disintegration | LDH leakage assay | PC-3 | Prostate cancer | GI50 : 1.24 ± 0.23 µM |
| dbacp01162 | Antimicrobial peptide TsAP-1 | MQIKHLITLFFLVLIVADQCSAFLSLIPSLVGGSISAFKGRRKREISAQIEQYKDLQKREAELEELLDRLPMY | Brazilian scorpion | Membrane disruption | MTT Cell viability assay | PC-3 | androgen-independent Prostate adenocarcinoma | IC50 : 0.83 - 2.0 μM |
| dbacp01390 | Aurein-3.3 [Cleaved into: Aurein-3.3.1] | GLFDIVKKIAGHIVSSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | PC-3 | Prostate cancer | IC50 : 5 μM |
| dbacp01432 | B1AW | FLPLLAGLAANFLPQIICKIARKC | Wuyi torrent frog | Cell membrane penetration | MTT assay | PC-3 | Human prostatic cancer | IC50 : 33.46 μM |
| dbacp01437 | B1AW-K | FLPLLAGLAANFLPKIICKIARKC | Wuyi torrent frog | Cell membrane penetration | MTT assay | PC-3 | Prostate cancer | IC50 : 33.46 μM |
| dbacp01451 | Bassianolide nonribosomal cyclodepsipeptide synthetase | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDYFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDGHGRVFSLQPTTDLTESENGDHLSTPASERTVVIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCALNQSVSKVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTAGDDEIHQVLEESEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVRNAGDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQAVVGRCITVDDDLVQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICVPSDHDRMHNIPGFIRQNQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKIDDSSRDPNNLGWAIGAHSWIINPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQVVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEDTFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFRTQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFTQLKVEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILRVEEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAQVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLERVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGSDELTRPVHPIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDETSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYPAEPGVRTLFQFPTDNDVRMSAPLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | PC-3M | Prostate cancer | Not found |
| dbacp01454 | Bassianolide nonribosomal cyclodepsipeptide synthetase (BSLS) | MEPPNNANTGQLGPTLPNGTVDLPTDLSREITRHFGLEQDEIEEILPCTPFQRDVIECASDDKRRAVGHVVYEIPEDVDTERLAAAWKATVRYTPALRTCIFTSETGNAFQVVLRDCFIFARMYCPSAHLKSAIVKDEATAAVAGPRCNRYVLTGEPNSKRRVLVWTFSHSFVDSAFQGRILQQVLAAYKDEHGRVFSLQPTTDLVESENGDCLSTPASERTVGIERATQFWQEKLHGLDASVFPHLPSHKRVPAIDARADHYLPCPPFIQHEWSSTTVCRTALAILLARYTHSSEALFGVVTEQSHEEHPLLLDGPTSTVVPFRVLCAPNQSVSEVMEAITTYDHDMRQFAHAGLCNISRIGDDASAACGFQTVLMVTDSRTASADEIHHVLEEPEKFIPCTDRALLLSCQMTDEGVLLVARYDQSILEPLQMARFLRQLGFLINKLQSTDGSPCVGQLDVLAPEDRTEIEGWNSEPLQTQDCLIHSEVVKNADDTPNKPAVCAWDGEWTYSELNNVSSRLASYISSLDLGQQLIVPIYLEKSKWVMAAILAVLKAGHAFTLIDPNDPPARTAQIIKQASASIALTSALHQSKMQTVVGRCITVDDDLFQTLTTFEGSQVASAAKPGDLAYVIFTSGSTGDPKGIMIEHRAFYSSVVKFGKALGIRSSTRALQFATHGFGAFLLEVLTTLIHGGCICIPSDHDRMHNIPGFIRQSQINWMMATPSYMTTMKPEDVPGLETLVLVGEQMSSSINDVWLSELQLLDGYGQSESSSICFVGKISDSSRDPNNLGRAIGSHSWIVNPDNPDQLVPIGAIGELLIESPGIARGYLFSQSTETPFLERAPAWYASKQPPYGVKFYRTGDLARYAPDGTVICLGRMDSQVKIRGQRVELDAIENLLRRQFPSDVTVVAEAVKRSDLPSSVVITGFLISSEYVVGAPSTEDTYILDQAVTQEINAKMRQILPAHSIPSFYICMKSLPRTATGKVDRRKLRSIGSSLLALQAQSTAPRSSQAPDASAGVTKLEEVWMDIFNLTPNSHNIGGNFFALGGDSITAIKMVnMARAAGIQLKVSDIFQNPTLASLQAAIGGSSMTVTSIPALALDGPVEQSYSQGRLWFLDQLEIGANWYTIPYAVRLRGPLDVDALNRALLALEKRHETLRTTFEDQDGVGVQIIHETLLDQLRIINADHADYVQLLKQEQTAPFNLASESGWRVSLIRLDDDDNILSIVMHHIISDGWSIDVLRRELGQLYAAALHGADLFGSALSPLPIQYRDFSVWQKQDAQVAEHERQLQYWQKQLADCSPAKLPTDFHRPALLSGKATTVPVTITSELYYRLQEFCSTFNTTSFVVLLATFRAAHYRLTGVDDAVIGTPIANRNRHELENLIGFFVNTQCMRITINEDEETFESLVRQVRSTTTAAFEHEDVPFERVVSAMLPGSRDLSQNPLAQLVFAIHSHKDLGKFELEALESEPLQNEVYTRFDAEFHFFQAPDGLTGYINFATELFKVETIQNVVSVFLQILRHGLEHPQTLISVVPLTDGLAELRSMGLLEIKKVEYPRDSSVVDVFATQVASYPDTLAVVDSSSRLTYAELDHQSDLLATWLRQQNLPTEALVVVLAPRSCETIITFLGILKANLAYLPLDIRSPITRMRDVLSTLPGRTIALLCSDEVAPDFQLPSIELVRIADALEEAAGMTSLNGHEHVPVPSPSPTSLAYVLYTSGSTGRPKGVMIEHRAIVRLARSDIIPDYRPACGDTMAHMFNTAFDGATYEIYTMLLNGGTLVCVDYMDTLSPKSLEAVFKKEQVNATIMAPALLKLYLADARDALKGLDVLISGGDRFDPQDAVDAQSLVRGSCYNGYGPTENGVFSTVYKVDKNDPFVNGVPLGRAVNNSGAYVVDRNQQLVGPGIIGELVVTGDGLARGYTERAFDQNRFIQLKIEGQSVRGYRTGDRVRYRVGEGLIEFFGRMDFQFKIRSNRIEAGEVEAAILSHPAVRNAAVILHVQEKLEPEIVGFVVAEHDDTAEQEEAGDQVEGWQAFFESTTYTELDTVSSSEIGKDFKGWTSMYDGNEIDKAEMQEWLDDTIHTLTDGQALGHVLEIGTGSGMVLFNLGSGLQSFVGLEPSKSAAAFVNNAIKSTPALAGKAHVFVGTATDTNKLDDLHPDLVIFNSVLQYFPTRDYLEQVVDALVHLRSAKRIFFGDVRSYATNRHFLAARAIYTLGNHTTKDEVRKKMAEMEEREEEFLVEPAFFTTLVNRLPDVRHVEIIPKnMQATNELSAYRYAAVVHLRGPDELTRPVHLIKMDDWVDFQASHMHKDALREYLRLAENTKTVAISNIPYGKTIFERQVVESLDDTSEDAPHASLDGAAWISAVRSDAKARSSLSVPDLVLLAKETGFRVEVSAARQWSQSGALDAVFHRYHPAEPDVRTLFQFPTDNDVRMSALLTNQPLQRLQKRRVAVQVREWLQDRIPSYMIPSHIVALDQMPLNTSGKVDRKELSRQAKAIKKVQKSAPPTAPAFPLSEVEVMLCEELTKTFEMDVNITDDFFQLGGHSLLATRLVARISHRLGARLTVKDVFDYPVFSELADIIRQQLASKNTLLPTASAGGGGQDKKESAGVAPTTDMEAMLCEEFANILGMDVGITDNFFDLGGHSLMATRLAARIGHRLNTTISVKDIFSHPVIFQLSAKLEVSQLESSSGGTDIKMPDYTAFQLIPAADAEKFMQDHIYPQINFSQDMVQDVYLATHLQQCFLRDVFGRPKPLVPFYVEFPPDSNPHTLATACTSLVDKYDIFRTIFVEAEGNLYQVVLKHLNLDIDVVETDANVHKTSSDLVDAIAKEPVRLGQPMIQVKVLKQTSSVRVLLWLSHALYDGLSWEHIVRDLHILSKERSLPPATQFSRYMQYVDHTRGPGCDFWRDVLQNAPITNLSDAGSGGRPTKAGDPRVWHAGKVISGPSQAIRSSITQATVFNAACAIVLSKETGTDNVVFGRIVSGRQGLPVRWQNIIGPCTNAVPVRAVVDAHGNHQQMLRDLQEQYLLSLPYETIGFDEIKRSCTDWPDSARNYGCCVTYQNFEYHPESEVDQQRVEMGILAKKAELIKEEPLYNVAIAGEVEPDGVHLQVTVVVDSQLFSQEGATHLMEQVCNTFQALNASL | White muscardine disease fungus | Cell apoptosis | Not specified | PC-3M | Prostate cancer | Not found |
| dbacp01460 | Bax 1 | STKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 2.0 μmol/L |
| dbacp01464 | Bax 10 | KLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01468 | Bax 11 | LSECLKRIGDELDSN | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01472 | Bax 12 | STKKLECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01476 | Bax 13 | STKKLCLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01480 | Bax 14 | STKKLLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01484 | Bax 15 | STKKLSECLGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01488 | Bax 16 | STKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 20 μmol/L |
| dbacp01492 | Bax 17 | TKKLSECLKRIGDEL | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 79 μmol/L |
| dbacp01496 | Bax 18 | TKKLSECLKRIGDE | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01500 | Bax 2 | AAKKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 2.3 μmol/L |
| dbacp01504 | Bax 3 | STKKLSECLKRIGDELDS | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 18.3 μmol/L |
| dbacp01508 | Bax 4 | STKKLSECLKRIGDELDSM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 7.6 μmol/L |
| dbacp01512 | Bax 5 | STKKLSECLKRIGDELDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 2.1 μmol/L |
| dbacp01516 | Bax 6 | STKKLSECLKRIGDELM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 8.0 μmol/L |
| dbacp01520 | Bax 7 | STKKLSECLKRIGDEM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 7.4 μmol/L |
| dbacp01524 | Bax 8 | STKKLSECLKRIGDM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : > 500 μmol/L |
| dbacp01528 | Bax 9 | KKLSECLKRIGDELDSnM | Effectors (BAK, BAX) | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 148.0 μmol/L |
| dbacp01589 | BCP-A | WPP | Marine invertebrates | Inducing apoptosis | Not specified | PC-3 | Not specified | IC50 : 1.99 mg/ml |
| dbacp01923 | Brevinin-1-AW | FLPLLAGLAANFLPQIICKIARKC | Skin secretion, the Wuyi torrent frog, China, Asia | Cell membrane penetration | MTT assay | PC-3 | Prostate cancer | IC50 : 33.46 μM |
| dbacp01942 | Brevinin-1H | FALGAVTKVLPKLFCLITRKC | Hainan Torrent Frog | Membrane disruption | MTT assay | PC-3 | Prostate cancer | IC50 : 3.37 to 5.87 µM |
| dbacp02045 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 12 µg/ml |
| dbacp02110 | cMastoparan-C(cMP-C) | CLNLKALLAVAKKILC | Synthetic construct | Apoptosis | MTT assay | PC-3 | Human prostate carcinoma | IC50 : 13.87 μM |
| dbacp02653 | Dermaseptin PS4 | MDILKKSIFLVLFLGLVSLSICEEEKRENEDEEKQEDDEQSEEKRALWKTLLKHVGKAAGKAALNAVTDMVNQGEQ | Sauvage's leaf frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | PC-3 | Prostate cancer | MIC : 10−9 to 10−4 M |
| dbacp02659 | Dermaseptin-B3 | ALWKnMLKGIGKLAGQAALGAVKTLVGAE | Giant leaf frog | Membrane lysis | In vitro proliferation assay, Soft agar assay | PC-3 | Human epithelial prostate adenocarcinoma | EC50 : 2 μM |
| dbacp02667 | Dermaseptin-PD-1 | GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ | Skin Secretion, Mexican leaf frog, Mexico, North America | Destroy plasma membrane | MTT assay | PC-3 | Human prostate carcinoma | IC50 : 10-4 and 10-9 M |
| dbacp02670 | Dermaseptin-PD-2 | GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI | Skin Secretion, Mexican leaf frog, Mexico, North America | Destroy plasma membrane | MTT assay | PC-3 | Human prostate carcinoma | IC50 : 3.17 μM |
| dbacp02673 | Dermaseptin-PD1 | GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ | Mexican leaf frog | Destroy plasma membrane | MTT assay | PC-3 | Prostate carcinoma | IC50 : 3.17 μM |
| dbacp02676 | Dermaseptin-PD2 | GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI | Mexican leaf frog | Destroy plasma membrane | MTT assay | PC-3 | Prostate carcinoma | IC50 : 3.17 μM |
| dbacp02682 | Dermaseptin-PH | ALWKEVLKNAGKAALNEINNLVQ | Northern orange-legged leaf frog | Cell membrane permeabilization | Bioactivity assessment assay, MTT cell proliferation assay | PC-3 | Not specified | IC50 : 11.8 μM |
| dbacp02687 | Dermaseptin-PH | ALWKEVLKNAGKAALNEINNLV | Orange-legged leaf frog, Northern orange-legged leaf frog, South America | Cell membrane permeabilization | MTT cell proliferation assay | PC-3 | Human prostate carcinoma | IC50 : 11.8 μM |
| dbacp02692 | Dermaseptin-PH | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PC-3 | Prostate carcinoma | IC50 : 17.44 - 49.51 μM |
| dbacp02708 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Brain tumor | IC50 : 21.78 μM |
| dbacp02709 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Breast cancer | IC50 : 21.78 μM |
| dbacp02710 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Pancreatic cancer | IC50 : 21.78 μM |
| dbacp02711 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Lung cancer | IC50 : 21.78 μM |
| dbacp02712 | Dermaseptin-PH (DRS-PH) | MDILKKSLFLILFLGVVSLSICEEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Prostate cancer | IC50 : 21.78 μM |
| dbacp02729 | Dermaseptin-PS4 | ALWKTLLKHVGKAAGKAALNAVTDMVNQ | Waxy monkey tree frog | Membrane disruption | Lactate dehydrogenase (LDH) cytotoxicity assay, MTT assay | PC-3 | Prostate cancer | MIC : 10−9 to 10−4 M |
| dbacp02735 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Brownbelly leaf frog | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PC-3 | Prostate carcinoma | IC50 : 8.64 - 18.51 μM |
| dbacp02740 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Skin secretion, Brownbelly leaf frog, Purchased in Peru, South America | Disruption of cell membranes | MTT assay, Lactate dehydrogenase (LDH) assay | PC-3 | Prostate carcinoma | IC50 : 8.64 - 18.51 μM |
| dbacp02744 | Dex-(KW)3 | KWKWKW | Synthetic | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | At 10 µM 60% viablity |
| dbacp02828 | EGFR-related peptide | ERRP | EGFR-related peptide | Apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | 30% Cell viability at 5 µg/ml |
| dbacp02976 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 47.69 µM |
| dbacp02983 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 47.69 µM |
| dbacp02990 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 :29.10 µM |
| dbacp02997 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 29.10 µM |
| dbacp03004 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 46.51 µM |
| dbacp03011 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 46.51 µM |
| dbacp03018 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 24.32 µM |
| dbacp03025 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 24.32 µM |
| dbacp03030 | Gageostatin A | ELLVDLL | Bacillus subtilis | Perturbation of the cell membrane | Sulforhodamine B (SBR) assay | PC-3 | Prostate cancer | GI50 : 4.6–19.6 μg/mL |
| dbacp03285 | Hc-CATH | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Green paddy frog | Not specified | MTT assay | PC-3 | Liver cancer | 3.63% cell death at 200 µg/ml |
| dbacp03286 | Hc-CATH | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Green paddy frog | Not specified | MTT assay | PC-3 | Prostate cancer | 3.63% cell death at 200 µg/ml |
| dbacp03291 | HECI | TVLRGCWTFSFPPKPCI | Hylarana erythraea | Cell membrane disintegration | MTT anti-proliferation assay | PC-3 | Prostate cancer | MIC : 1µM |
| dbacp03319 | hP1 | HSHRDFQPVLHLVALNSPLSGGMRG | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | 39% inhibition at 7 mg/kg/d |
| dbacp03320 | hP2 | MRGIRGADFQAFQQARAVGLAGTFR | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | 19% inhibition at 7 mg/kg/d |
| dbacp03321 | hP3 | TFRAFLSSRLQDLYSIVRRADRAAV | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | No inhibition at 7 mg/kg/d |
| dbacp03322 | hP4 | AAVPIVNLKDELLFPSWEALFSGSE | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | No inhibition at 7 mg/kg/d |
| dbacp03323 | hP5 | GSEGPLKPGARIFSFDGKDVLRHPT | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | 29% inhibition at 7 mg/kg/d |
| dbacp03324 | hP6 | HPTWPQKSVWHGSDPNGRRLTESY | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | No inhibition at 7 mg/kg/d |
| dbacp03325 | hP7 | ETWRTEAPSATGQASSLLGGRLLGQ | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | No inhibition at 7 mg/kg/d |
| dbacp03326 | hP8 | LGQSAASAHHAYIVLAIENSFMTASKKK | Human endostatin peptides | Anti-angiogenesis | Matrigel assay | BxPC-3 | Pancreatic cancer | No inhibition at 7 mg/kg/d |
| dbacp03341 | Human placenta hydrolysate (HPH) | NA | Human | Not specified | Not specified | PC-3 | Prostate cancer | IC50 : 1.3-2.8 mg/ml |
| dbacp03373 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | BXPC-3 | Pancreatic cancer | IC50 : 6.8 µMol/L |
| dbacp03500 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Brain tumor | IC50 : 9.97μM |
| dbacp03501 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Breast cancer | IC50 : 9.97μM |
| dbacp03502 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Pancreatic cancer | IC50 : 9.97μM |
| dbacp03503 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Lung cancer | IC50 : 9.97μM |
| dbacp03504 | K8, 23-DPT9 | MDILKKSKFLILFLGVVSLSICKEEKRENEEEMEQDDEQSEMKRALWKEVLKNAGKAALNEINNLVQGGQ | Northern orange-legged leaf frog | Disruption of cell membranes | MTT assay | PC-3 | Prostate cancer | IC50 : 9.97μM |
| dbacp03754 | LHRH–BH3 peptide luteinizing hormone-releasing hormone (LHRH) | QHWSYGLRPGMGQVGRQLAIIGDDINRRY | Effectors (BAK, BAX) | Inducing apoptosis | Cytotoxicity assay, MTT assay | PC-3 | Prostate cancer | Not found |
| dbacp04342 | Lycosin-1 | Ac-KGWFKAMKSIAKFIAKEKLKEHL-amide | Tarantula wolf spider | Inhibit the migration of prostate cancer cell; Induce apoptosis | MTT assay | PC-3 | Prostate cancer | MIC : 20 μM |
| dbacp04347 | Lytic | KLlLKlLkkLLKlLKKK | Interleukin-4 receptor a (IL-4Ra) chain | Induction of apoptosis | WST-1 assay | BXPC-3 | Pancreatic cancer | IC50 : 37.1 µMol/L |
| dbacp04496 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : >200 µg/ml |
| dbacp04514 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 53 µg/ml |
| dbacp04524 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 41 µg/ml |
| dbacp04540 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | IC50 : 47 µg/ml |
| dbacp04575 | Mastoparan-C | LNLKALLAVAKKIL | European hornet | Apoptosis | MTT assay | PC-3 | Human prostate carcinoma | IC50 : 1.4 μM |
| dbacp04580 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | PC-3 | Human prostate carcinoma | MIC : 6.26 - 36.65 μM |
| dbacp04586 | Mastoparan-Cimals. XXA; UCLL1c) | LNLKALLAVAKKIL | Venom, the European Hornet | Inducing apoptosis | MTT cell viability assay and Lactate dehydrogenase (LDH) leakage assay | PC-3 | Human prostate carcinoma | IC50 : < 4 μM |
| dbacp04595 | Mauriporin | MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR | Fat-tailed scorpion | Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis | MTT assay, Lactate dehydrogenase (LDH) Release assay | PC-3 | Human Prostate cancer | IC50 : 27.9 μM - 283.3 μM |
| dbacp04869 | NK-2 (Mammals, Animals) | KILRGVCKKIMRTFLRRISKDILTGKK | Mammal | Not specified | MTT assay | PC-3 | Not found | IC50 : 4.1 μM |
| dbacp04873 | NK-dpro (Derived from NK-2) | KILPGVCKKIMRPFLRRISKDILTGKK | Synthetic construct | Not specified | MTT assay | PC-3 | Not found | IC50 : 9.6 μM |
| dbacp04877 | NK-pro (Derived from NK-2) | KILRGVCKKIMRPFLRRISKDILTGKK | Synthetic construct | Not specified | MTT assay | PC-3 | Not found | IC50 : 9.3 μM |
| dbacp05550 | Phylloseptin-PHa | FLSLIPAAISAVSALANHF | Northern orange-legged leaf frog | Disruption of the membrane | MTT assay, Lactate dehydrogenase (LDH) assay | PC-3 | Human prostate carcinoma | LD50 : < 5 µM |
| dbacp05667 | Protein GPR15LG (Antimicrobial peptide with 57 amino acid residues) (AP-57) (Antimicrobial peptide-57) (Colon-derived SUSD2 binding factor) (CSBF) (Protein GPR15 ligand) (Protein GPR15L) (Secreted protein C10orf99) | MRLLVLSSLLCILLLCFSIFSTEGKRRPAKAWSGRRTRLCCHRVPSPNSTNLKGHHVRLCKPCKLEPEPRLWVVPGALPQV | Human | Cytotoxic effects | SDS-PAGE assay | PC-3 | Colorectal cancer | Not found |
| dbacp05720 | PTP4 | FLKLLKKLAAKFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 18.63 µg/ml |
| dbacp05725 | PTP5 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | Not found |
| dbacp05730 | PTP6 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 13.27 µg/ml |
| dbacp05735 | PTP7 | FLGALFKALSKLL | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 5.01 µg/ml |
| dbacp05740 | PTP8 | FLKLLAGLLKNFA | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 28.9 µg/ml |
| dbacp05804 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Lung cancer | IC50 : 283.90 µM |
| dbacp05805 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Prostate cancer | IC50 : 283.90 µM |
| dbacp05806 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Breast cancer | IC50 : 283.90 µM |
| dbacp05807 | R2PLx-22 | GIMDTVKNAAKNLAGQLLDKLK | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Glioma | IC50 : 283.90 µM |
| dbacp05885 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Lung cancer | IC50 : 5.79 µM |
| dbacp05886 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Prostate cancer | IC50 : 5.79 µM |
| dbacp05887 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Breast cancer | IC50 : 5.79 µM |
| dbacp05888 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Glioma | IC50 : 5.79 µM |
| dbacp05903 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCKITAC | Gram-negative purple non-sulfur bacteria | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | PC-3 | Human prostate carcinoma | IC50 : 5.79 µM |
| dbacp05908 | Ranatuerin-2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Skin secretions, the pickerel frog, North America | Inducing apoptosis | MTT Cell viability assay and Lactate dehydrogenase (LDH) leakage assay | PC-3 | Human prostate carcinoma | IC50 : 5.79 µM |
| dbacp05992 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Lung cancer | IC50 : 792.60 µM |
| dbacp05993 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Prostate cancer | IC50 : 792.60 µM |
| dbacp05994 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Breast cancer | IC50 : 792.60 µM |
| dbacp05995 | S−24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Not found | Inducing apoptosis | MTT and LDH assay | PC-3 | Glioma | IC50 : 792.60 µM |
| dbacp06028 | SCH-P10 | DYVP | Marine invertebrates | Inducing apoptosis | MTT assay | PC-3 | Prostate cancer | IC50 : 1.09 mg/mL |
| dbacp06030 | SCH-P9 | LPGP | Marine invertebrates | Inducing apoptosis | MTT assay | PC-3 | Prostate cancer | IC50 : 1.09 mg/mL |
| dbacp06059 | Sepia ink oligopeptide (SIO) | QPK | Not found | Inducing apoptosis | CCK-8 assay | PC-3 | Prostate cancer | IC50 : < 5 mg/mL |
| dbacp06185 | t Mastoparan-C(tMP-C, Tat (49-57)-Mastoparan-C) | RKKRRQRRRLNLKALLAVAKKIL | Synthetic construct | Apoptosis inducing | MTT assay | PC-3 | Human prostate carcinoma | IC50 : 3.86 μM |
| dbacp06206 | TAT-CTMP4 | LDPKLMKEEQMSQAQLFTRSFDDGL | Not found | Inducing apoptosis | Not specified | BxPC-3 | Pancreatic cancer | TAT-CTMP4 induced a dose-dependent increase in apoptosis as detected by %-TUNEL positive cells and %-active caspase-3 (% active caspase-3 ranged from 31.2 to 61.9 at the highest dose tested (10 µM). |
| dbacp06269 | Temporin-PE | FLPIVAKLLSGLL | Skin secretions, Common water frog or green frog, Europe | Destabilization of membranes | MTT assay | PC-3 | Lung cancer | TI : 10μM |
| dbacp06273 | Temporin-PE | FLPIVAKLLSGLL | Skin secretions, Common water frog or green frog, Europe | Destabilization of membranes | MTT assay | PC-3 | Human neuronal glioblastoma | TI : 10μM |
| dbacp06277 | Temporin-PE | FLPIVAKLLSGLL | Skin secretions, Common water frog or green frog, Europe | Destabilization of membranes | MTT assay | PC-3 | Human prostate carcinoma | TI : 10μM |
| dbacp06281 | Temporin-PE | FLPIVAKLLSGLL | Skin secretions, Common water frog or green frog, Europe | Destabilization of membranes | MTT assay | PC-3 | Melanoma | TI : 10μM |
| dbacp06285 | Temporin-PE | FLPIVAKLLSGLL | Skin secretions, Common water frog or green frog, Europe | Destabilization of membranes | MTT assay | PC-3 | Human prostate carcinoma | TI : approx. 10μM |
| dbacp06363 | TsAP-2 | FLGMIPGLIGGLISAFK | Venom-derived cDNAlibrary of the Brazilian yellow scorpion | Not specified | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 13.3 µM |
| dbacp06371 | TsAP-S1 | FLSLIPKLVKKIIKAFK | Derivative of TsAP-1, Brazilian yellow scorpion venom peptide | Not specified | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 2.1 µM |
| dbacp06379 | TsAP-S2 | FLGMIPKLIKKLIKAFK | Derivative of TsAP-1, Brazilian yellow scorpion venom peptide | Not specified | MTT/MTS assay | PC-3 | Prostate cancer | IC50 : 1.6 µM |
| dbacp06544 | YALPAG | YALPAG | Not found | Inducing apoptosis | Not specified | PC-3 | Not found | IC50 : 42.0 mg/ml |
| dbacp06545 | YALPAH | YALPAH | Not found | Inducing apoptosis | Not specified | PC-3 | Not found | IC50 : 11.3 mg/ml |
| dbacp06546 | YALPAR | YALPAR | Not found | Inducing apoptosis | Not specified | PC-3 | Not found | IC50 : 13.1 mg/ml |
| dbacp06547 | YALRAH | YALRAH | Not found | Inducing apoptosis | Not specified | PC-3 | Not found | IC50 : 8.1 mg/ml |
| dbacp06566 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | Not found |
| dbacp06582 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | PC-3 | Prostate cancer | Not found |
| dbacp06600 | ZXR-1 | FKIGGFIKKLWRSKLA | Venom base | Inducing apoptosis | MTT assay | PC-3 | Not found | IC50 : 69.1 ± 1.6 µM |
| dbacp06617 | LA3IK | LAIAVK | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 321.4 ± 11.79 µM |
| dbacp06621 | D-LA3IK | laiavk | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 98.71 ± 6.17 µM |
| dbacp06625 | LA3IK-SCR | LAKAVI | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 319 ± 13.64 µM |
| dbacp06629 | RP-7 | RPPCVIL | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 113 ± 8.02 µM |
| dbacp06633 | D-RP-7 | rppcvil | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 101 ± 5.73 µM |
| dbacp06637 | RP7 SCR | RPPLVIC | Migration and invasion enhancer 1 (MIEN1) | Targeting the MIEN1 signaling pathway | MTT assay | PC-3 | Prostate Cancer | IC50 = 128 ± 11.65 µM |
| dbacp06670 | Crabrolin | FLPLILRKIVTAL | European hornet (Vespa crabro) | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 32.13 μM |
| dbacp06675 | Crabrolin-4R | FLPRILRKIVTAL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 17.98 μM |
| dbacp06680 | Crabrolin-4K | FLPKILRKIVTAL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 20.58 μM |
| dbacp06685 | Crabrolin-TR | FLPRILRKIVRAL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 3.944 μM |
| dbacp06690 | Crabrolin-FR | RLPRILRKIVRAL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 15.87 μM |
| dbacp06695 | Crabrolin-AR | RLPRILRKIVRRL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 28.78 μM |
| dbacp06700 | Crabrolin-PR | RLRRILRKIVRRL | Synthetic Analog of Crabrolin | Not available | MTT assay | PC-3 | Prostate Cancer | IC50 = 22.37 μM |
| dbacp06867 | Pep-1-Phor21 | CGEMGWVRCKFAKFAKKFAKFAKKFAKFAK | Hybrid peptide PEP1 and Phor 21 | Not available | AlamarBlue assay | PC-3 | Prostrate Cancer | IC50 ≤ 0.6 μM |
| dbacp06883 | trichoderin A | MDA-P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderma sp. fungus, strain 05FI48 | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06885 | trichoderin A analogue 4 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06886 | trichoderin A analogue 12 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 > 1 μM |
| dbacp06887 | trichoderin A analogue 13 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 > 1 μM |
| dbacp06888 | trichoderin A analogue 14 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.6 μM |
| dbacp06889 | trichoderin A analogue 15 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.5 μM |
| dbacp06890 | trichoderin A analogue 16 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06891 | trichoderin A analogue 17 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.4 μM |
| dbacp06892 | trichoderin A analogue 18 | P-Cha-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.2 μM |
| dbacp06902 | trichoderin A analogue 19 | MDA-P-AHMOD-Aib-Aib-IV-Aib-Aib-AMAE | Trichoderin A | Apoptosis inducing | PrestoBlue assay | BxPC-3 | Pancreatic Cancer | IC50 = 0.1 μM |
| dbacp07028 | [G10a]-SHa | FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | PC-3 | Prostate Cancer | IC50 = 13.04 ± 1.99 µM |
| dbacp07035 | [G10a]2-SHa | FLSGIVGMLaKLFKFLKaLMFLSGIVG | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | PC-3 | Prostate Cancer | IC50 = 6.31 ± 0.66 µM |
| dbacp07042 | [G10a]3-SHa | FLSGIVGMLaKLFFLSGIVGMLaKLFFLSGIVGMLaKLFKK | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | PC-3 | Prostate Cancer | IC50 = 1.84 ± 0.17 µM |
| dbacp07048 | Jeff-[G10a]2-SHa | FLSGIVGMLaKLF-jeff-FLSGIVGMLaKLF | Analog of temporin SHa | Dendrimerization enhances stability, selectivity, anticancer efficacy | Resazurin dye assay | PC-3 | Prostate Cancer | IC50 = 57.99 ± 5.04 µM |
| dbacp07051 | Temporin-PKE | FLPLIIGALSSLLPKIF | skin secretion of Pelophylax kl. esculentus | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 7.29 μM |
| dbacp07056 | Temporin-PKE-2K | FLPLIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 2.64 μM |
| dbacp07061 | Temporin-PKE-K12 | FLPLIIGALSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 27.32 μM |
| dbacp07066 | Temporin-PKE-3K | FLPKIIGKLSSLLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 3.01 μM |
| dbacp07071 | Temporin-PKE-4K | FLPKIIGKLSSKLPKIF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 49.50 μM |
| dbacp07076 | Temporin-PKE-i | FLPLIIGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 3.35 μM |
| dbacp07081 | Temporin-PKE-3i | FLPLiiGALSSLLPKiF | Synthetic | Charge-optimized membranolysis induces apoptosis. | MTT assay | PC-3 | Prostate Cancer | IC50 = 167 μM |
| dbacp07108 | Nigrocin-M1 | GLLGKILGAGKKVLLGVSGLL | Synthetic | Membrane disruption mediates selective cytotoxicity. | MTT assay | PC-3 | Prostate cancer | IC50 = 31.27 μM |
| dbacp07259 | t-DPH1-K4 | GLWKKIKNVAAAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 18.99 μM |
| dbacp07263 | t-DPH1-5K | GLWKKIKNVAKAAGKAALGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 2.605 μM |
| dbacp07267 | t-DPH1-6K | GLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 55.65 μM |
| dbacp07271 | t-DPH1-6KW | WLWKKIKNVAKAAGKAAKGAL | Analogue of t-DPH1 | Membrane disruption induces apoptotic signaling. | MTT assay | PC-3 | Prostate Cancer | IC50 = 118.4 μM |
| dbacp07313 | B1OS-L | FLPLIASLAGNVVPKIFCKITKRC | B-1OS | Not Available | MTT assay | PC-3 | Prostate Cancer | IC50 = 5.473 µM |
| dbacp07318 | B1OS-D-L | FlPLIASLAGNVVPKIFCKITKRC | B-1OS | Not Available | MTT assay | PC-3 | Prostate Cancer | IC50 = 2.629 µM |
| dbacp07398 | Pugnin A | RLMRIFRILKLAR | Synthetic | Membrane disruption induces necrotic death | MTT assay | PC-3 | Prostate Cancer | 74% Cytotoxicity at 100 µM |
| dbacp07400 | Pugnin B | RMMRIFWVIKLAR | Synthetic | Membrane disruption induces necrotic death | MTT assay | PC-3 | Prostate Cancer | 90% Cytotoxicity at 100 µM |
| dbacp07410 | Dermaseptin-TO | ALWKDLLKNVGIAAGKAALNKVTDMVNQ | Phyllomedusa tomopterna | Membrane disruption induces cell death | MTT assay | PC-3 | Prostate Cancer | Graph Figure-7 |
| dbacp07480 | (LLKK)4 linear peptide | LLKKLLKKLLKKLLKK | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | PC-3 | Prostate Cancer | Cell Viability (%) ~ 17.1 ± 5.0 at 30 µg/mL |
| dbacp07484 | 2-arm branched peptide | [LLKKLLKK]2kC | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | PC-3 | Prostate Cancer | Cell Viability (%) ~ 73.5 ± 2.2 at 30 µg/mL |
| dbacp07488 | 4-arm branched peptide | {[LLKKLLKK]2kC}2 | Synthetic | Apoptosis, drug-resistance reversal, tumor suppression | MTT assay | PC-3 | Prostate Cancer | Cell Viability (%) ~ 49.0 ± 0.8 at 30 µg/mL |
| dbacp07501 | Brevinin-1Ha | FALGAVTCLIRTKCKVLPKLF | Analogue of Brevinin-1H | α-helix enhances antimicrobial, anticancer activity | MTT assay | PC-3 | Prostate Cancer | IC50 = 186.9 µM |
| dbacp07505 | Brevinin-1HY | FALGAVTKVLYKLFCLITRKC | Analogue of Brevinin-1H | α-helix enhances antimicrobial, anticancer activity | MTT assay | PC-3 | Prostate Cancer | IC50 = 5.425 µM |
| dbacp07514 | Dermaseptin-PP | ALWKDMLKGIGKLAGKAALGAVKTLV | Phyllomedusa palliata | Membrane disruption triggers dual apoptosis | MTT assay | PC-3 | Prostate Cancer | IC50 = 4.15 μM |
| dbacp07852 | Dermaseptin-PT9 | GLWSKIKDAAKTAGKAALGFVNEMV | Phyllomedusa tarsius | Membrane disruption and cationic enhancement | MTT assay | PC-3 | Prostate Cancer | IC50 = 21.78 µM |
| dbacp07857 | K8, 23-DPT9 | GLWSKIKKAAKTAGKAALGFVNKMV | Synthetic | Membrane disruption and cationic enhancement | MTT assay | PC-3 | Prostate Cancer | IC50 = 9.97 µM |
| dbacp07863 | HN-1 | FALGAVTKLLPSLLCMITRKC | Amolops hainanensis | Apoptosis induction and immune activation | MTT assay | PC-3 | Prostate Cancer | Not Available |
| dbacp07870 | R-Lycosin I derivative 8a | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | PC-3 | Prostate Cancer | IC50 = 6.9 ± 0.4 µM |
| dbacp07876 | R-Lycosin I derivative 8b | RGWFRAMRSIARFIARERLRGHL | Monosaccharide Analogue of Anticancer Peptide R-Lycosin-I | GLUT1-mediated uptake enhances cytotoxicity | CCK-8 assay | PC-3 | Prostate Cancer | IC50 = 4.9 ± 0.2 µM |
| dbacp07951 | S-24-R2PLx | GIMDTVKNAAKNLAGQLLDKLKCSITAC | Synthetic Analogue of Ranatuerin-2PLx | R2PLx induces caspase-dependent apoptosis | MTT assay | PC-3 | Prostate Cancer | IC50 = 792.60 µM |
| dbacp07957 | DP-2 | GRKKRRQRRRGALWKSLLKNVGKA | Synthetic | DRS-DU-1 induces selective tumor cytotoxicity | MTT assay | PC-3 | Prostate Cancer | IC50 = 6.75 μM |
| dbacp07990 | K5, 17-DPS3 | ALWKKILKNAGKAALNKINQIVQ | Analogue of Dermaseptin-PS3 | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | PC-3 | Prostate Cancer | IC50 = 18.20 μM |
| dbacp07992 | L10, 11-DPS3 | ALWKDILKNLLKAALNEINQIVQ | Analogue of Dermaseptin-PS3 | Enhanced cationicity/hydrophobicity increases cytotoxicity | MTT assay | PC-3 | Prostate Cancer | IC50 = 1.85 μM |
| dbacp08066 | Temporin-PE | FLPIVAKLLSGLL | Pelophylax kl. esculentus | Modulates membrane interactions | MTT assay | PC-3 | Prostate Cancer | IC50 = 38.56 μM |
| dbacp08070 | temporin-PEa | FLYIVAKLLSGLL | Synthetic analog of Temporin-PE | Modulates membrane interactions | MTT assay | PC-3 | Prostate Cancer | IC50 = 27.62 μM |
| dbacp08074 | temporin-PEb | FLPIVAKLLSGLLGRKKRRQRRR | Synthetic analog of Temporin-PE | Modulates membrane interactions | MTT assay | PC-3 | Prostate Cancer | IC50 = 3.051 μM |
| dbacp08153 | IL-1 | FKAGGFIKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 58.4 ± 13.7 μM |
| dbacp08156 | IL-2 | FKIGGFAKKLWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 43.6 ± 7.9 μM |
| dbacp08159 | IL-3 | FKIGGFIKKAWRSLLA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 74.9 ± 13.3 μM |
| dbacp08162 | IL-4 | FKIGGFIKKLWRSALA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 35.5 ± 3.9 μM |
| dbacp08165 | IL-5 | FKIGGFIKKLWRSLAA | Synthetic | Ile/Leu residues crucially mediate cytolysis | MTT assay | PC-3 | Prostate Cancer | IC50 = 22.0 ± 2.6 μM |
| dbacp08177 | Peptide - 1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | PC-3 | Prostate Cancer | Not Available |
| dbacp08270 | ZXR-2 | FKIGGFIKKLWRSLLA | Synthetic | Not Available | MTT assay | PC-3 | Prostate Cancer | IC50 = 14.2 ± 0.5 μM |
| dbacp08313 | P1C | YKSIEFC | Synthetic | Not Available | Cell Proliferation assay | BXPC-3 | Pancreatic Cancer | ~40% reduction in cell growth at 20 μM |
| dbacp08318 | Sample Peptide 2 from US011339203B2 | FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | PC-3 | Prostate Cancer | Cell Viability = 2.5% at 25 μM |